BNP和NT-proBNP在新生儿心血管疾病中的应用进展  

Application progress of BNP and NT-proBNP in neonates

作　　者：尹娅 潘沅[1] 周宏伟[1] 沈薇[2] YIN Ya;PAN Yuan;ZHOU Hongwei;SHEN Wei(Department of Clinical Laboratory,Zhujiang Hospital of Southern Medical University,Guangzhou 510282,Guangdong,China;Department of Neonatology,Nanfang Hospital of Southern Medical University,Guangzhou 510515,Guangdong,China)

机构地区：[1]南方医科大学珠江医院检验医学部,广东广州510282 [2]南方医科大学南方医院新生儿科,广东广州510515

出　　处：《检验医学》2023年第6期518-523,共6页Laboratory Medicine

基　　金：广州市重点领域研发计划脑科学与类脑研究重大科技专项(202206060001)。

摘　　要：B型钠尿肽(BNP)和氨基末端B型钠尿肽原(NT-proBNP)是心肌细胞分泌的生物标志物,是反映心脏结构和功能的敏感指标。在新生儿人群中,血浆BNP和NT-proBNP水平的参考区间目前尚无统一标准,但已有较多研究探索了其在新生儿心血管疾病诊断、疗效监测和预后评估中的应用价值。文章对相关研究进展进行综述,以便为临床应用提供参考。B-type natriuretic peptide(BNP)and N-terminal pro-B-type natriuretic peptide(NT-proBNP)are blood markers secreted by cardiomyocytes and sensitive indicators reflecting cardiac structure and function.There is no consensus on the reference ranges of plasma levels of BNP and NT-proBNP in neonates,but many studies have explored the application in the diagnosis assessment,therapeutic monitoring and prognostic evaluation for neonatal cardiovascular diseases.This review mainly summarizes the above aspects in order to provide guidance for clinical application.

关 键 词：B型钠尿肽 氨基末端B型钠尿肽原 新生儿 心血管疾病 疗效监测 预后 

分 类 号：R446.1[医药卫生—诊断学]